Is the CannTrust Holdings’s (TSX:TRST) Scandal an Opportunity for Investors?

CannTrust Holdings Inc (TSX:TRST)(NYSE:CTST) is experiencing some turmoil, but could this be good news for investors?

Going against the grain

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

There has been no shortage of drama within the marijuana sector. One of the most prominent concerned is Aphria — one of the leading Canadian cannabis companies. Aphria shed much of its share value after allegations that the firm had overpaid for various acquisitions it had made in South America came to light. While it took some time, Aphria now seems to have left these allegations behind, but the company had to pay a hefty price to do so.

Aphria’s CEO was pushed out of the door, an investigation into the allegations was launched, and the company incurred a $50 million non-cash impairment charge as a result. Another major marijuana company is currently dealing with some major drama of its own: CannTrust Holdings (TSX:TRST)(NYSE:CTST). 

Troubling revelations

In case you aren’t caught up, CannTrust recently revealed it received a non-compliance report from Health Canada. This was as a result of the firm growing over 5,000 kilograms of cannabis in unlicensed rooms. Though weed is now legal in Canada, growers still have to abide by some stringent rules, and it seems CannTrust was in blatant violation of some of these rules. Further, top management was aware of these non-compliant activities and did absolutely nothing. Naturally, CannTrust needs to do something to gain the trust of investors back. 

The company recently took a step towards that goal by firing CEO Peter Aceto and forcing President Eric Paul to resign. CannTrust also put a hold on over 7,000 kilograms of cannabis grown in these rooms and temporary halted medical and recreational cannabis sales. As one would expect, shares of CannTrust plunged as a result of this debacle. There will be more consequences down the road. CannTrust’s financial results will almost certainly feel the full impact of this fiasco.

Is this an opportunity?

Just because CannTrust’s shares are down doesn’t necessarily mean now is a good time to purchase them. That depends on whether the company will safely rebound from this setback and what value it offers investors to begin with. The first of these questions is likely easily answered. Sure, CannTrust will have to wait some time before it can completely break free from this episode. Corporations have had to deal with much worse, after all. That aside, though, are there any good reasons to consider CannTrust? Here is why one might answer that question in the affirmative. 

Other than CannTrust being one of about a dozen companies in Canada that is projected to break the 100,000-kilograms-per-year production-capacity mark, the Ontario-based pot grower also benefits from its strategically located greenhouses. CannTrust grows much of its cannabis in nutrient-rich water solvents (unlike most of its competitors who do it in soil) — a feat made possible because it benefits from easy access to water and electricity. This strategy will likely allow CannTrust to grow cannabis at lower costs than the average, which, all other things remaining equal, will lead to higher margins. 

The bottom line

It will be critical to observe how the drama surrounding CannTrust evolves in the next few weeks. Whatever happens, though, investors should seriously consider purchasing shares of CannTrust now. As the old adage goes: buy low and sell high. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Bakiny has no position in any of the stocks mentioned.  

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »